# Dr. Hönle AG Germany - High-tech Engineering



**Buy** (old: Buy) **26-May-25** 

**Price target: EUR 17.00** (old: EUR 17.00)

Price: EUR 10.30 Next result: Q3'25: 07.08.25
Bloomberg: HNL GR Market cap: EUR 63.4 m
Reuters: HNLG.DE Enterprise Value: EUR 113.3 m

tim.wunderlich@ha-ib.de Tel.: +49 40 4143885 81

Tim Wunderlich, CFA

**Analyst** 

20101440

## **Turning the corner - Confirm Buy**

**Fiscal Q2 results beat expectations**, as demand from curing and disinfection applications picked up materially, and as cost savings took effect. With this, **Hönle looks fully on track to reach the FY'24/25E guidance**, which it confirmed (€ 95-105m sales / >€ 5.5m EBITDA). See page two.

**Q2** sales increased by 6% yoy to € 25.8m (eHAIB: € 22.8m), driven by strength in Disinfection (+13% yoy to € 7.3m) across end-markets food and ballast water treatment. Hönle is also successfully tapping new markets, having won its first € 50k installation with an undisclosed semi customer for the treatment of ultrapure process water. On the back of a strong project pipeline comprising several other semi(-related) clients, management expects revenue from this new vertical to reach up to € 300k this fiscal year, rising to € 1m in the next fiscal year.

The Curing segment delivered 12% yoy revenue growth to € 9.4m, courtesy of a demand rebound from industrial applications, while the important printing vertical stabilised and remained flat yoy. In late May, König & Bauer made positive remarks about the impact of the China Print Trade fair, stating that group order intake is flat YTD with the backlog sitting at record levels. This provides confidence that Hönle will see stronger momentum in printing in the coming months, supported by the previously announced strategic win of a new printing industry client, who should contribute € 1m to segment sales this FY (eHAIB).


**Adhesives was the only soft performer in the quarter** (sales -4% yoy to € 9.0m) due to reduced orders from the automotive and electronics end-markets.

**Fiscal Q2 EBITDA declined by -5% yoy to € 2.0m**, but doubled qoq and beat eHAIB of € 1.8m. The main headwind was the Adhesives segment, where unfavourable mix effects led to a significant margin decline. Curing benefitted from cost savings – with more to come in fiscal H2 – and Disinfection revealed economies of scale and positive mix effects, which triggered remarkable segment EBITDA growth. See page two for details.

Overall, the results underscore that the strategic initiatives are yielding positive effects and support the view that Hönle has achieved a sustainable operational turnaround. **Buy with a € 17.00 PT based on DCF**. continued

Y/E 30.9 (EUR m)	2020/21	2021/22	2022/23	2023/24	2024/25E	2025/26E	2026/27E
Sales	115.2	116.1	106.3	98.7	100.2	110.4	122.5
Sales growth	23 %	1%	-8 %	-7 %	1%	10 %	11 %
EBITDA	13.8	12.1	0.4	3.1	7.0	11.2	14.8
EBIT (inc revaluation net)	0.3	5.8	-9.4	-10.3	2.0	6.2	9.8
Net income	-4.8	-13.4	-11.0	-13.3	0.2	3.2	5.8
Net debt	41.5	52.3	47.5	45.7	45.6	44.5	41.9
Net gearing	37.5 %	48.9 %	49.6 %	57.6 %	57.2 %	53.8 %	47.4 %
Net Debt/EBITDA	3.0	4.3	119.3	14.8	6.5	4.0	2.8
EPS pro forma	-0.80	0.44	-1.87	-2.19	0.03	0.52	0.95
CPS	-2.04	-1.72	0.02	0.42	0.03	0.16	0.46
Gross profit margin	58.6 %	53.6 %	51.1 %	59.6 %	60.1 %	60.7 %	61.3 %
EBITDA margin	12.0 %	10.4 %	0.4 %	3.1 %	7.0 %	10.1 %	12.1 %
EBIT margin	0.3 %	5.0 %	-8.9 %	-10.4 %	2.0 %	5.6 %	8.0 %
ROCE	0.2 %	3.3 %	-5.7 %	-6.9 %	1.4 %	4.4 %	6.8 %
EV/sales	2.9	1.8	1.6	1.1	1.1	1.0	0.9
EV/EBITDA	24.2	16.9	426.0	36.7	16.2	10.1	7.4
EV/EBIT	958.6	35.0	-18.0	-11.1	56.3	18.2	11.2
PER	-59.0	55.5	-10.5	-4.8	325.7	20.1	11.0
Adjusted FCF yield	0.1%	3.7 %	-1.8 %	-0.8 %	3.5 %	6.1 %	8.7 %

Source: Company data, Hauck Aufhäuser Investment Banking Close price as of: 23.05.2025



Source: Company data, HAIB

High/law EQ washed

nightiow 52 weeks:	20.10 / 0.00
Price/Book Ratio:	0.8
Relative performance (SD	AX):
3 months	-7.7 %
6 months	-7.4 %
12 months	-582%

#### Changes in estimates

		<u>Sales</u>	EBIT	<b>EPS</b>
2025	old:	100.2	2.0	0.03
2023	Δ	-	-	-
2026	old:	110.4	6.2	0.52
2020	Δ	-	-	-
2027	old:	122.5	9.8	0.95
Δ	-	-	-	

#### Key share data:

Number of shares: (in m pcs)	6.1
Authorised capital: (in € m)	-
Book value per share: (in €)	13.1
Ø trading volume: (12 months)	16,200

#### Major shareholders:

Free Float	61.7 %
Peter Möhrle GmbH	25.4 %
Hans-Joachim Vits	4.2 %
Lazard	4.0 %
Quaero	2.9 %

#### Company description:

Leading supplier of adhesives for consumer electronics, as well as of equipment, systems and lamps for the printing industry

#### Company guidance 2025E:

€ 95-105m sales / >€ 5.5m EBITDA

EUR	Q2 2025	<b>Q2 2025</b> est	Q2 2024	yoy	Q12025	qoq
Sales	25.8	22.8	24.3	6%	21.4	20%
Adhesives	9.0	8.8	9.4	-4%	8.1	11%
Curing	9.4	7.7	8.4	12%	7.6	24%
Disinfection	7.3	6.3	6.5	13%	5.7	29%
EBITDA	2.0	1.8	2.1	-5%	1.0	93%
EBITDA margin	7.7%	7.9%	8.6%	- 0.9 pp	4.8%	+2.9 pp
Adhesives	0.8	1.5	2.0	-60%	1.1	-27%
Margin	8.9%	17.0%	21.4%	- 12.5 pp	13.6%	- 4.7 pp
Curing	0.0	-0.3	-0.6	n.a.	-0.6	n.a.
Margin	0.3%	-3.9%	-6.8%	+ 7.2 pp	-7.9%	+ 8.2 pp
Disinfection	1.2	0.6	0.6	90%	0.5	133%
Margin	15.9%	9.5%	9.4%	+ 6.5 pp	8.8%	+7.1pp
Net Profit	0.2	0.1	0.2	7.2%	-0.6	n.a.
Net margin	0.8%	0.4%	0.7%	+ 0.0 pp	-2.8%	+3.6 pp
EPS	0.03	0.02	0.03	7.2%	-0.10	n.a.

#### Company in a Nutshell

Dr Hoenle is a specialist for UV lamps and systems that are used in the printing industry to dry / harden ink, for the disinfection of water and surfaces as well as for the simulation of sunlight in the automotive industry. It also offers adhesives for specialised niche applications in consumer electronics, automotive, medical, and other verticals.

Curing accounts for 38% of group sales, Adhesives for 36%, and Disinfection for 26%.


## **Upcoming Catalysts**


Hoenle has undergone an overdue management change and is in the process of **implementing a large number of efficiency measures** that should return the company to stronger growth and higher margins within 12-18 months. We expect an improved operating performance in FY'25E, as well as evidence that efficiency measures are taking effect, to serve as a valuation catalysts going forward.

#### **Investment Case**

- Technology leader for UV systems and adhesives with a focus on niche applications
- A patchy track record but better times ahead: a new management team has implemented overdue efficiency measures to return Hönle to stronger growth and higher margins within 12-18 months
- Sales are seen to rise by 7% CAGR'24-27E to € 123m in FY'27E as management is re-focusing the company on growing markets and is investing into key account management and sales & marketing to improve execution
- EBITDA should rise to € 15m by FY'27E from € 3m in 2024 on the back of efficiency measures and a strong operating leverage due to idle capacity
- While the stock does not look cheap on NTM multiples, smooth execution of the new strategy could result in upside to estimates. **Buy with a** € 17.00 PT based on DCF

#### **Key Performance Indicators**





Cash flow summary	2022/23	2023/24	2024/25E	2025/26E	2026/27E
Operating cash flow	3.1	5.5	3.2	4.0	5.8
Capex	2.9	2.1	3.0	3.0	3.2
FCF	0.2	3.4	0.2	1.0	2.6
FCF per share	0.0	0.6	0.0	0.2	0.4
FCF yield	-1.8 %	-0.8 %	3.5 %	6.1 %	8.7 %
Net Debt/EBITDA	119.3	14.8	6.5	4.0	2.8

Source: Company data, Hauck Aufhäuser Investment Banking

15.0		EBIT			10%
10.0			6%	8%	5%
5.0		2%	6.2	9.8	0%
0.0	23 24E	2.0 25E	26E	27E	-5%
-5.0	-9.4 -9%				070
-10.0	-10%				-10%
-15.0					-15%
	EBIT		adj.) EBIT mar	gin (%)	

Source: Company data, Hauck Aufhäuser Investment Banking

Key ratios summary	2022/23	2023/24	2024/25E	2025/26E	2026/27E
EPS growth	-17.6 %	20.7 %	-101.5 %	1522.9 %	82.6 %
Capital Turnover	0.7	0.7	0.7	0.8	0.8
Avg. working capital / sales	40.6 %	39.6 %	41.0 %	41.0 %	41.0 %
Cash conversion cycle (days)	249.9	278.8	291.2	294.8	297.9
FCF / Net profit	neg.	neg.	91.7 %	32.1 %	45.1 %
Interest cover	0.0	0.0	1.1	3.4	5.4

## **Financials**

Profit and loss (EUR m)	2020/21	2021/22	2022/23	2023/24	2024/25E	2025/26E	2026/27E
Net sales	115.2	116.1	106.3	98.7	100.2	110.4	122.5
Sales growth	22.7 %	0.8 %	-8.4 %	-7.2 %	1.5 %	10.2 %	11.0 %
Increase/decrease in finished goods and work-in-process	3.1	2.1	-1.9	-1.4	1.0	1.0	1.7
Total sales	118.3	118.2	104.5	97.3	101.2	111.4	124.3
Other operating income	1.6	3.6	3.3	2.2	2.0	2.0	2.2
Material expenses	48.9	54.8	51.1	39.3	40.4	43.8	48.0
Personnel expenses	39.7	39.7	39.5	41.3	40.3	41.6	45.2
Other operating expenses	17.4	15.2	16.7	15.8	15.5	16.8	18.4
Total operating expenses	104.5	106.1	104.1	94.2	94.2	100.2	109.4
EBITDA	13.8	12.1	0.4	3.1	7.0	11.2	14.8
Depreciation	9.8	4.6	8.2	12.0	4.2	4.2	4.2
EBITA	4.0	7.6	-7.8	-8.9	2.8	7.0	10.6
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	3.7	1.7	1.6	1.4	0.8	0.8	0.8
Impairment charges	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT (inc revaluation net)	0.3	5.8	-9.4	-10.3	2.0	6.2	9.8
Interest income	0.1	0.1	0.3	0.1	0.1	0.1	0.1
Interest expenses	1.1	1.5	1.8	2.1	1.8	1.8	1.8
Other financial result	0.0	0.0	0.0	0.1	0.0	0.0	0.0
Financial result	-1.0	-1.4	-1.6	-2.0	-1.7	-1.7	-1.7
Recurring pretax income from continuing operations	-0.6	4.4	-11.0	-12.2	0.3	4.4	8.1
Extraordinary income/loss	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Earnings before taxes	-0.6	4.4	-11.0	-12.2	0.3	4.4	8.1
Taxes	4.3	1.6	0.3	0.8	0.1	1.3	2.4
Net income from continuing operations	-4.9	2.8	-11.3	-13.0	0.2	3.2	5.8
Result from discontinued operations (net of tax)	0.0	16.0	-0.3	0.0	0.0	0.0	0.0
Net income	-4.9	-13.2	-10.9	-13.0	0.2	3.2	5.8
Minority interest	0.0	0.2	0.1	0.3	0.0	0.0	0.0
Net profit (reported)	-4.8	-13.4	-11.0	-13.3	0.2	3.2	5.8
Average number of shares	6.1	6.1	6.1	6.1	6.1	6.1	6.1
EPS reported	-0.80	-2.20	-1.82	-2.19	0.03	0.52	0.95

Profit and loss (common size)	2020/21	2021/22	2022/23	2023/24	2024/25E	2025/26E	2026/27E
Net sales	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %
Increase/decrease in finished goods and work-in-process	2.7 %	1.8 %	neg.	neg.	1.0 %	0.9 %	1.4 %
Total sales	102.7 %	101.8 %	98.2 %	98.5 %	101.0 %	100.9 %	101.4 %
Other operating income	1.4 %	3.1 %	3.1 %	2.2 %	2.0 %	1.8 %	1.8 %
Material expenses	42.5 %	47.2 %	48.1 %	39.8 %	40.3 %	39.7 %	39.2 %
Personnel expenses	34.4 %	34.2 %	37.2 %	41.9 %	40.2 %	37.7 %	36.9 %
Other operating expenses	15.1 %	13.1 %	15.7 %	16.0 %	15.5 %	15.2 %	15.0 %
Total operating expenses	90.7 %	91.4 %	97.9 %	95.4 %	94.0 %	90.8 %	89.3 %
EBITDA	12.0 %	10.4 %	0.4 %	3.1 %	7.0 %	10.1 %	12.1 %
Depreciation	8.5 %	3.9 %	7.7 %	12.1 %	4.2 %	3.8 %	3.4 %
EBITA	3.5 %	6.5 %	neg.	neg.	2.8 %	6.3 %	8.7 %
Amortisation of goodwill	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Amortisation of intangible assets	3.2 %	1.5 %	1.5 %	1.4 %	0.8 %	0.7 %	0.7 %
Impairment charges	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
EBIT (inc revaluation net)	0.3 %	5.0 %	neg.	neg.	2.0 %	5.6 %	8.0 %
Interest income	0.1 %	0.1 %	0.2 %	0.1 %	0.1 %	0.1 %	0.1 %
Interest expenses	1.0 %	1.3 %	1.7 %	2.1 %	1.8 %	1.6 %	1.5 %
Other financial result	0.0 %	0.0 %	0.0 %	0.1 %	0.0 %	0.0 %	0.0 %
Financial result	neg.	neg.	neg.	neg.	neg.	neg.	neg.
Recurring pretax income from continuing operations	neg.	3.8 %	neg.	neg.	0.3 %	4.0 %	6.6 %
Extraordinary income/loss	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Earnings before taxes	neg.	3.8 %	neg.	neg.	0.3 %	4.0 %	6.6 %
Tax rate	n/a	n/a	n/a	n/a	29.0 %	29.0 %	29.0 %
Net income from continuing operations	neg.	2.4 %	neg.	neg.	0.2 %	2.9 %	4.7 %
Income from discontinued operations (net of tax)	0.0 %	13.8 %	-0.3 %	0.0 %	0.0 %	0.0 %	0.0 %
Net income	neg.	neg.	neg.	neg.	0.2 %	2.9 %	4.7 %
Minority interest	neg.	0.1 %	0.1 %	0.3 %	0.0 %	0.0 %	0.0 %
Net profit (reported)	neg.	neg.	neg.	neg.	0.2 %	2.9 %	4.7 %

Balance sheet (EUR m)	2020/21	2021/22	2022/23	2023/24	2024/25E	2025/26E	2026/27E
Intangible assets	24.0	23.3	19.7	12.6	12.5	12.3	12.3
Property, plant and equipment	87.8	79.6	75.1	71.6	69.8	67.9	66.2
Financial assets	1.4	1.4	1.4	0.5	0.5	0.5	0.5
FIXED ASSETS	113.2	104.2	96.3	84.8	82.8	80.8	79.0
Inventories	46.7	46.4	35.0	30.5	33.4	36.8	40.8
Accounts receivable	17.1	19.7	15.6	14.9	14.7	16.2	18.0
Other current assets	9.0	15.0	14.8	12.0	12.0	12.0	12.0
Liquid assets	12.1	7.1	9.3	7.5	7.7	8.7	11.3
Deferred taxes	4.9	3.0	5.2	5.8	5.8	5.8	5.8
Deferred charges and prepaid expenses	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CURRENT ASSETS	89.7	91.2	79.9	70.6	73.5	79.4	87.9
TOTAL ASSETS	202.9	195.5	176.2	155.4	156.3	160.2	166.8
SHAREHOLDERS EQUITY	110.7	106.9	95.8	79.4	79.6	82.8	88.5
MINORITY INTEREST	0.4	0.4	0.3	0.3	0.3	0.3	0.3
Long-term debt	49.7	33.1	44.4	40.3	40.3	40.3	40.3
Provisions for pensions and similar obligations	8.6	4.0	3.2	4.4	4.4	4.4	4.4
Other provisions	3.0	2.2	1.7	1.5	1.5	1.5	1.5
Non-current liabilities	61.3	39.3	49.3	46.2	46.2	46.2	46.2
short-term liabilities to banks	3.9	26.4	12.4	13.0	13.0	13.0	13.0
Accounts payable	9.4	10.3	7.6	6.4	7.1	7.8	8.7
Advance payments received on orders	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other liabilities (incl. from lease and rental contracts)	16.5	11.3	9.5	9.4	9.4	9.4	9.4
Deferred taxes	0.7	1.0	1.2	0.8	0.8	0.8	0.8
Deferred income	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Current liabilities	30.5	49.0	30.7	29.5	30.3	31.0	31.9
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	202.9	195.5	176.2	155.4	156.3	160.2	166.8

Balance sheet (common size)	2020/21	2021/22	2022/23	2023/24	2024/25E	2025/26E	2026/27E
Intangible assets	11.8 %	11.9 %	11.2 %	8.1 %	8.0 %	7.7 %	7.4 %
Property, plant and equipment	43.3 %	40.7 %	42.6 %	46.1 %	44.7 %	42.4 %	39.7 %
Financial assets	0.7 %	0.7 %	0.8 %	0.3 %	0.3 %	0.3 %	0.3 %
FIXED ASSETS	55.8 %	53.3 %	54.6 %	54.6 %	53.0 %	50.4 %	47.3 %
Inventories	23.0 %	23.7 %	19.9 %	19.6 %	21.4 %	23.0 %	24.5 %
Accounts receivable	8.4 %	10.1 %	8.9 %	9.6 %	9.4 %	10.1 %	10.8 %
Other current assets	4.4 %	7.7 %	8.4 %	7.7 %	7.6 %	7.5 %	7.2 %
Liquid assets	6.0 %	3.6 %	5.3 %	4.8 %	4.9 %	5.4 %	6.8 %
Deferred taxes	2.4 %	1.6 %	2.9 %	3.7 %	3.7 %	3.6 %	3.5 %
Deferred charges and prepaid expenses	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
CURRENT ASSETS	44.2 %	46.7 %	45.4 %	45.4 %	47.0 %	49.6 %	52.7 %
TOTAL ASSETS	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %
SHAREHOLDERS EQUITY	54.6 %	54.7 %	54.4 %	51.1 %	50.9 %	51.7 %	53.1 %
MINORITY INTEREST	0.2 %	0.2 %	0.2 %	0.2 %	0.2 %	0.2 %	0.2 %
Long-term debt	24.5 %	16.9 %	25.2 %	25.9 %	25.8 %	25.1 %	24.1 %
Provisions for pensions and similar obligations	4.2 %	2.1 %	1.8 %	2.8 %	2.8 %	2.8 %	2.6 %
Other provisions	1.5 %	1.1 %	1.0 %	1.0 %	1.0 %	0.9 %	0.9 %
Non-current liabilities	30.2 %	20.1 %	28.0 %	29.7 %	29.5 %	28.8 %	27.7 %
short-term liabilities to banks	1.9 %	13.5 %	7.0 %	8.4 %	8.3 %	8.1 %	7.8 %
Accounts payable	4.6 %	5.3 %	4.3 %	4.1 %	4.5 %	4.9 %	5.2 %
Advance payments received on orders	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Other liabilities (incl. from lease and rental contracts)	8.1 %	5.8 %	5.4 %	6.1 %	6.0 %	5.9 %	5.6 %
Deferred taxes	0.3 %	0.5 %	0.7 %	0.5 %	0.5 %	0.5 %	0.5 %
Deferred income	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Current liabilities	15.0 %	25.0 %	17.4 %	19.0 %	19.4 %	19.3 %	19.1 %
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %

Cash flow statement (EUR m)	2020/21	2021/22	2022/23	2023/24	2024/25E	2025/26E	2026/27E
Net profit/loss	-4.9	-13.2	-10.9	-13.0	0.2	3.2	5.8
Depreciation of fixed assets (incl. leases)	9.8	4.6	9.8	12.0	4.2	4.2	4.2
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	3.7	1.7	0.0	1.4	0.8	0.8	0.8
Others	3.9	15.9	4.8	2.8	0.0	0.0	0.0
Cash flow from operations before changes in w/c	23.0	9.0	3.6	3.2	5.2	8.2	10.8
Increase/decrease in inventory	-11.5	-11.6	-1.8	4.6	-2.9	-3.4	-4.0
Increase/decrease in accounts receivable	-2.8	-2.6	4.0	0.7	0.2	-1.5	-1.8
Increase/decrease in accounts payable	2.9	0.9	-2.7	-1.2	0.7	0.7	0.9
Increase/decrease in other working capital positions	0.0	-3.1	0.0	-1.8	0.0	0.0	0.0
Increase/decrease in working capital	-11.3	-16.4	-0.5	2.3	-2.0	-4.2	-5.0
Cash flow from operating activities	1.1	-7.4	3.1	5.5	3.2	4.0	5.8
CAPEX	17.1	4.4	2.9	2.1	3.0	3.0	3.2
Payments for acquisitions	7.7	0.0	0.0	0.7	0.0	0.0	0.0
Financial investments	-0.1	0.1	-0.6	0.2	0.0	0.0	0.0
Income from asset disposals	0.2	2.8	5.0	0.6	0.0	0.0	0.0
Cash flow from investing activities	-24.5	-1.7	2.7	-2.4	-3.0	-3.0	-3.2
Cash flow before financing	-12.9	-9.1	5.8	3.2	0.2	1.0	2.6
Increase/decrease in debt position	4.3	4.9	-3.3	-4.8	0.0	0.0	0.0
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Dividends paid	3.0	1.2	0.1	0.1	0.0	0.0	0.0
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Effects of exchange rate changes on cash	0.0	0.4	-0.2	0.0	0.0	0.0	0.0
Cash flow from financing activities	1.2	3.7	-3.4	-4.9	0.0	0.0	0.0
Increase/decrease in liquid assets	-11.6	-4.9	2.2	-1.7	0.2	1.0	2.6
Liquid assets at end of period	12.1	7.1	9.3	7.5	7.7	8.7	11.3

Quarterly results (EUR m)	Q3 22/23	Q4 22/23	Q1 23/24	Q2 23/24	Q3 23/24	Q4 23/24	Q1 24/25	Q2 24/25	Q3 24/25E	FY 24/25E
Sales	26.2	26.6	23.8	24.3	23.9	26.7	21.4	25.8	26.3	100.2
Sales growth	-1 %	-8 %	-14 %	-6 %	-9 %	0 %	-10 %	6%	10 %	1%
Gross profit	4.9	17.6	14.3	15.0	14.8	15.3	13.9	15.5	15.4	60.8
Gross profit margin	18.7 %	66.0 %	59.9 %	61.7 %	62.0 %	57.4 %	64.9 %	60.2 %	58.6 %	60.1%
EBITDA	-9.1	2.8	0.7	2.1	1.3	-1.0	1.0	2.0	2.0	7.0
EBITDA margin	-34.5 %	10.4 %	2.7 %	8.6 %	5.5 %	-3.6 %	4.7 %	7.7 %	7.6 %	7.0 %
EBIT (inc revaluation net)	-10.5	-2.6	-0.8	0.7	0.0	-10.2	-0.4	0.6	0.8	2.0
EBIT margin	-40.1 %	-9.7 %	-3.3 %	2.8 %	0.0 %	-38.1 %	-1.7 %	2.4 %	3.1 %	2.0 %
EPS reported	-1.52	-0.72	-0.15	0.03	-0.04	-2.03	-0.10	0.03	0.05	0.03

Key ratios (EUR m)	2020/21	2021/22	2022/23	2023/24	2024/25E	2025/26E	2026/27
P&L growth analysis							
Sales growth	22.7 %	0.8 %	-8.4 %	-7.2 %	1.5 %	10.2 %	11.0 %
EBITDA growth	-7.0 %	-12.3 %	-96.7 %	676.1 %	127.1 %	59.1 %	32.9 %
EBIT growth	-95.7 %	1572.5 %	-261.4 %	9.0 %	-119.6 %	205.7 %	59.6 %
EPS growth	-177.2 %	177.1 %	-17.6 %	20.7 %	-101.5 %	1522.9 %	82.6 %
-							
Efficiency							
Total operating costs / sales	90.7 %	91.4 %	97.9 %	95.4 %	94.0 %	90.8 %	89.3 %
Sales per employee	184.4	176.6	171.2	166.8	171.3	188.1	202.4
EBITDA per employee	22.1	18.4	0.6	5.2	12.0	19.0	24.5
Balance sheet analysis							
Avg. working capital / sales	42.3 %	47.5 %	46.5 %	41.7 %	40.0 %	39.1%	38.9 %
Inventory turnover (sales/inventory)	2.5	2.5	3.0	3.2	3.0	3.0	3.0
Trade debtors in days of sales	54.1	61.8	53.6	55.2	53.6	53.6	53.6
A/P turnover [(A/P*365)/sales]	29.9	32.4	25.9	23.5	25.9	25.9	25.9
Cash conversion cycle (days)	332.2	302.0	249.9	278.8	291.2	294.8	297.9
Cash flow analysis Free cash flow	-16.0	-11.8	0.2	3.4	0.2	1.0	2.6
Free cash flow/sales	-13.9 %	-10.2 %	0.2 %	3.5 %	0.2 %	0.9 %	2.1 %
FCF / net profit	neg.	neg.	neg.	neg.	91.7 %	32.1 %	45.1 %
Capex / depn	125.6 %	71.9 %	23.8 %	17.0 %	60.4 %	59.4 %	63.9 %
Capex / maintenance capex	76.3 %	172.8 %	184.3 %	181.7 %	80.0 %	76.7 %	81.7 %
Capex / sales	14.7 %	3.9 %	2.2 %	2.3 %	3.0 %	2.7 %	2.6 %
Security				.==			
Net debt	41.5	52.3	47.5	45.7	45.6	44.5	41.9
Net Debt/EBITDA	3.0	4.3	119.3	14.8	6.5	4.0	2.8
Net debt / equity	0.4	0.5	0.5	0.6	0.6	0.5	0.5
Interest cover	0.3	3.8	0.0	0.0	1.1	3.4	5.4
Dividend payout ratio	100.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Asset utilisation							
Capital employed turnover	0.7	0.7	0.7	0.7	0.7	0.8	0.8
Operating assets turnover	0.8	0.9	0.9	0.9	0.9	1.0	1.1
Plant turnover	1.3	1.5	1.4	1.4	1.4	1.6	1.9
Inventory turnover (sales/inventory)	2.5	2.5	3.0	3.2	3.0	3.0	3.0
Returns							
ROCE	0.2 %	3.3 %	-5.7 %	-6.9 %	1.4 %	4.4 %	6.8 %
ROE	-4.4 %	-12.5 %	-11.5 %	-16.7 %	0.2 %	3.8 %	6.5 %
Other Interest paid / avg. debt	2.2 %	2.7 %	3.1 %	3.8 %	3.4 %	3.4 %	3.4 %
No. employees (average)	625	658	621	592	585	587	606
Number of shares	6.1	6.1	6.1	6.1	6.1	6.1	6.1
DPS	0.2	0.0	0.0	0.0	0.0	0.0	0.0
EPS reported	-0.80	-2.20	-1.82	-2.19	0.03	0.52	0.95
El o lopolica	0.00	2.20	1.02	2.17	0.00	0.02	0.70
Valuation ratios							
P/BV	2.6	1.4	1.2	0.8	0.8	0.8	0.7
EV/sales	2.9	1.8	1.6	1.1	1.1	1.0	0.9
EV/EBITDA	24.2	16.9	426.0	36.7	16.2	10.1	7.4
EV/EBITA	83.4	27.0	-21.7	-12.8	40.3	16.1	10.3
		35.0	-18.0	-11.1	56.3	18.2	11.3
EV/EBIT	958.6	33.0	10.0			10.2	
	958.6 -21.0	-17.3	811.2	33.0	635.5	110.8	
EV/EBIT							42.2 8.7 % 0.0 %

Disclosures regarding research publications of Hauck Aufhäuser Lampe Privatbank AG pursuant to section 85 of the German Securities Trading Act (WpHG) and distributed in the UK through Hauck Aufhauser IB Ltd., subject to the FCA requirements on research recommendation disclosures

Pursuant to section 85 of the German Securities Trading Act (WpHG) a research report has to point out possible conflicts of interest in connection with the analysed company. Further to this, under the FCA's rules on research recommendations, any conflicts of interest in connection with the recommendation must be disclosed. A conflict of interest is presumed to exist in particular if Hauck Aufhäuser Lampe Privatbank AG

- (1) or any other person belonging to the same group with that person (as part of a consortium) within the past twelve months, acquired the financial instruments of the analysed company,
- (2) or any other person belonging to the same group with that person has entered into an agreement on the production of the research report with the analysed company,
- (3) has, within the past twelve months, been party to an agreement on the provision of investment banking services with the analysed company or have received services or a promise of services under the term of such an agreement,
- (4) holds a) 5% or more of the share capital of the analysed company, or b) the analysed company holds 5% or more of the share capital of Hauck Aufhäuser Lampe Privatbank AG or its affiliate(s),
- (5) holds a net short (a) or a net long (b) position of 0.5% of the outstanding share capital of the analysed company or derivatives thereof,
- (6) or any other person belonging to the same group with that person is a market maker or liquidity provider in the financial instruments of the issuer,
- (7) or the analyst has any other significant financial interests relating to the analysed company such as, for example, exercising mandates in the interest of the analysed company or a significant conflict of interest with respect to the issuer,
- (8) The research report has been made available to the company prior to its publication. Thereafter, only factual changes have been made to the report.

#### Conflicts of interest that existed at the time when this research report was published:

Company	Disclosure
Dr. Hönle AG	2,6

#### Historical target price and rating changes for Dr. Hönle AG in the last 12 months **Price and Rating History Initiation coverage Dr. Hönle AG as of 22/05/25** 14-May-20 24.00 22.00 20.00 18.00 16.00 14.00 12.00 10.00 8.00 6.00 01.25 06.24 07.24 08.24 09.24 10.24 11.24 12.24 02.25 03.25 04.25 05.25 Close (21/05/25) Target price Close Company Date **Analyst** Rating **Target price**

# Dr. Hönle AG

Dr. Hönle AG	28.02.2025	Wunderlich, Tim	Buy	EUR 17,00	EUR 9,88
	21.01.2025	Wunderlich, Tim	Buy	EUR 17,00	EUR 7,66
	10.12.2024	Wunderlich, Tim	Buy	EUR 17,00	EUR 8,26
	02.12.2024	Wunderlich, Tim	Buy	EUR 17,00	EUR 8,50
	13.08.2024	Wunderlich, Tim	Buy	EUR 19,00	EUR 16,95

Hauck Aufhäuser Investment Banking	a distribution of rating	s and in proportion t	o investment bankina services
	,		

Buy	71.36 %	84.38 %
Sell	4.23 %	3.13 %
Hold	24.41 %	12.50 %

#### 1. General Information/Liabilities

This research report has been produced for the information purposes of institutional investors only, and is not in any way a personal recommendation, offer or solicitation to buy or sell the financial instruments mentioned herein. The document is confidential and is made available by Hauck Aufhäuser Lampe Privatbank AG, distributed in the UK through Hauck Aufhäuser IB Ltd., exclusively to selected recipients [in DE, GB, FR, CH, US, UK, Scandinavia, and Benelux or, in individual cases, also in other countries]. A distribution to private investors in the sense of the German Securities Trading Act (WpHG) is excluded. It is not allowed to pass the research report on to persons other than the intended recipient without the permission of Hauck Aufhäuser Lampe Privatbank AG. Reproduction of this document, in whole or in part, is not permitted without prior permission Hauck Aufhäuser Lampe Privatbank AG. All rights reserved.

Under no circumstances shall Hauck Aufhäuser Lampe Privatbank AG, any of its employees involved in the preparation, have any liability for possible errors or incompleteness of the information included in this research report – neither in relation to indirect or direct nor consequential damages. Liability for damages arising either directly or as a consequence of the use of information, opinions and estimates is also excluded. Past performance of a financial instrument is not necessarily indicative of future performance.

#### 2. Responsibilities

This research report was prepared by the research analyst named on the front page (the "Producer"). The Producer is solely responsible for the views and estimates expressed in this report. The report has been prepared independently. The content of the research report was not influenced by the issuer of the analysed financial instrument at any time. It may be possible that parts of the research report were handed out to the issuer for information purposes prior to the publication without any major amendments being made thereafter.

#### 3. Organisational Requirements

Hauck Aufhäuser Lampe Privatbank AG took internal organisational and regulative precautions to avoid or accordingly disclose possible conflicts of interest in connection with the preparation and distribution of the research report. All members of Hauck Aufhäuser Lampe Privatbank AG involved in the preparation of the research report are subject to internal compliance regulations. No part of the Producer's compensation is directly or indirectly related to the preparation of this financial analysis. In case a research analyst or a closely related person is confronted with a conflict of interest, the research analyst is restricted from covering this company.

#### 4. Information Concerning the Methods of Valuation/Update

The determination of the fair value per share, i.e. the price target, and the resultant rating is done on the basis of the adjusted free cash flow (adj. FCF) method and on the basis of the discounted cash flow – DCF model. Furthermore, a peer group comparison is made.

The adj. FCF method is based on the assumption that investors purchase assets only at a price (enterprise value) at which the operating cash flow return after taxes on this investment exceeds their opportunity costs in the form of a hurdle rate of 7.5%. The operating cash flow is calculated as EBITDA less maintenance capex and taxes.

Within the framework of the DCF approach, the future free cash flows are calculated initially on the basis of a fictitious capital structure of 100% equity, i.e. interest and repayments on debt capital are not factored in initially. The adjustment towards the actual capital structure is done by discounting the calculated free cash flows with the weighted average cost of capital (WACC), which takes into account both the cost of equity capital and the cost of debt. After discounting, the calculated total enterprise value is reduced by the interest-bearing debt capital in order to arrive at the equity value.

Hauck Aufhäuser Lampe Privatbank AG uses the following three-step rating system for the analysed companies:

Buy: Sustainable upside potential of more than 10% within 12 months

Sell: Sustainable downside potential of more than 10% within 12 months.

Hold: Upside/downside potential is limited. No immediate catalyst visible.

NB: The ratings of Hauck Aufhäuser Lampe Privatbank AG are not based on a performance that is expected to be "relative" to the market.

The decision on the choice of the financial instruments analysed in this document was solely made by Hauck Aufhäuser Lampe Privatbank AG. The opinions and estimates in this research report are subject to change without notice. It is within the discretion of Hauck Aufhäuser Lampe Privatbank AG whether and when it publishes an update to this research report, but in general updates are created on a regular basis, after 6 months at the latest. A sensitivity analysis is included and published in company's initial studies.

#### 5. Major Sources of Information

Part of the information required for this research report was made available by the issuer of the financial instrument. Furthermore, this report is based on publicly available sources (such as, for example, Bloomberg, Reuters, VWD-Trader and the relevant daily press) believed to be reliable. Hauck Aufhäuser Lampe Privatbank AG has checked the information for plausibility but not for accuracy or completeness.

#### 6. Competent Supervisory Authority

Hauck Aufhäuser Lampe Privatbank AG are under supervision of the BaFin – German Federal Financial Supervisory Authority Bundesanstalt für Finanzdienstleistungsaufsicht), Graurheindorfer Straße 108, 53117 Bonn and Marie-Curie-Straße 24 – 28, 60439 Frankfurt a.M.

This document is distributed in the UK through Hauck Aufhauser IB Ltd. and in compliance with the applicable FCA requirements.

#### 7. Specific Comments for Recipients Outside of Germany

This research report is subject to the law of the Federal Republic of Germany. The distribution of this information to other states in particular to the USA, Canada, Australia and Japan may be restricted or prohibited by the laws applicable within this state.

#### 8. Miscellaneous

According to Article 4(1) No. i of the delegated regulation 2016/958 supplementing regulation 596/2014 of the European Parliament, further information regarding investment recommendations of the last 12 months are published under: https://www.hal-privatbank.com/en/investmentbank/investment-banking

## Disclosures for U.S. persons only

This research report is a product of HAUCK AUFHÄUSER LAMPE PRIVATBANK AG, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by HAUCK AUFHÄUSER LAMPE PRIVATBANK AG, only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, HAUCK AUFHÄUSER LAMPE PRIVATBANK AG, has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

## Contacts: Hauck Aufhäuser Investment Banking

#### **HAIB** Research

Hauck Aufhäuser Investment Banking Mittelweg 16/17 20148 Hamburg Germany Hauck Aufhäuser Investment Banking Goetheplatz 9-11 60313 Frankfurt am Main Germany Tel.: +49 (0) 40 414 3885 97 E-Mail: research@ha-ib.de www.ha-research.de

#### Tim Wunderlich, CFA

Head of Transactional Research Tel.: +49 40 414 3885 81 E-Mail: tim.wunderlich@ha-ib.de

## Marie-Thérèse Grübner

Head of Research Tel.: +49 40 450 6342 3097 E-Mail: marie-therese.gruebner@ha-ib.de

#### **Alexander Galitsa**

Analyst

Tel.: +49 40 414 3885 83 E-Mail: alexander.galitsa@ha-ib.de

#### **Christian Salis**

Analyst Tel.: +49 40 414 3885 96 E-Mail: christian.salis@ha-ib.de

#### Felix Kruse

Analyst Tel.: +49 40 414 3885 95 E-Mail: felix.kruse@ha-ib.de

#### Finn Kemper

Analyst Tel.: +49 40 450 6342 3098 E-Mail: finn.kemper@ha-ib.de

### Jorge González Sadornil

Analyst Tel.: +49 40 414 3885 84 E-Mail: jorge.gonzalez@ha-ib.de

#### Simon Keller, CFA

Analyst Tel.: +49 40 414 388 573 E-Mail: simon.keller@ha-ib.de

## **HAIB Sales**

#### Alexander Lachmann

Equity Sales Tel.: +41 43 49 73 023 E-Mail: alexander.lachmann@ha-ib.de

#### **Carlos Becke** Equity Sales

Tel.: +44 203 34 59 603 E-Mail: carlos.becke@ha-ib.de

## Carsten Kinder

Head of Equities Tel.: +41 43 49 73 024 E-Mail: carsten.kinder@ha-ib.de

#### **Christian Bybjerg**

Equity Sales
Tel.: +44 203 34 59 602
E-Mail: christian.bybjerg@ha-ib.de

#### Hugues Madelin

Equity Sales Tel.: +33 1 42 68 50 12 E-Mail: hugues.madelin@ha-ib.de

#### Imogen Voorspuy

Equity Sales
Tel: +44 203 34 59 601
E-Mail: imogen.voorspuy@ha-ib.de

## Markus Scharhag

Equity Sales Tel.: +49 89 23 93 28 13 E-Mail: markus.scharhag@ha-ib.de

## Vincent Bischoff

Equity Sales Tel.: +49 40 41 43 88 588 E-Mail: vincent.bischoff@ha-ib.de

## **HAIB** Trading

Hauck Aufhäuser Investment Banking Mittelweg 16/17 20148 Hamburg

Germany

Tel.: +49 40 414 3885 78 E-Mail: info@hal-privatbank.com www.hal-privatbank.com

#### Fin Schaffer

Trading
Tel.: +49 40 414 38 85 98
E-Mail: fin.schaffer@ha-ib.de

#### Carolin Heidrich

Middle-Office Tel.: +49 40 414 3885 87

E-Mail: carolin.heidrich@hal-privatbank.com

#### **Nils Carstens**

Tel.: +49 40 414 38 85 85 E-Mail: nils.carstens@ha-ib.de

#### **Tom Warlich**

Middle-Office Tel.: +49 40 414 3885 78

E-Mail: tom.warlich@hal-privatbank.com